Validation of a Computational Fluid Dynamics Model for a Novel Residence Time Distribution Analysis in Mixing at Cross-Junctions

[EN] In Water Distribution Networks, the chlorine control is feasible with the use of water quality simulation codes. EPANET is a broad domain software and several commercial computer software packages base their models on its methodology. However, EPANET assumes that the solute mixing at cross-junctions is ¿complete and instantaneous¿. Several authors have questioned this model. In this paper, experimental tests are developed while using Copper Sulphate as tracer at different operating conditions, like those of real water distribution networks, in order to obtain the Residence Time Distribution and its behavior in the mixing as a novel analysis for the cross-junctions. Validation tests are developed in Computational Fluid Dynamics, following the k-# turbulence model. It is verified that the mixing phenomenon is dominated by convection, analyzing variation of Turbulent Schmidt Number vs. experimental tests. Having more accurate mixing models will improve the water quality simulations to have an appropriate control for chlorine and possible contaminants in water distribution networks.To CONACYT for the Master and Ph.D. scholarships (417824 and 703220) to D.H.-C. and the Ph.D. scholarship (294038) to M.R.; To Universidad de Guanajuato for the financial support of the project No. 100/2018 of J.L.N.; To Engineering Division, Campus Guanajuato and Geomatics and Hydraulics Engineering Department for the financial support of this project; and finally, to SEP-PRODEP and UG for the financial support to publish this paper.Hernandez Cervantes, D.; Delgado Galván, XV.; Nava, JL.; López Jiménez, PA.; Rosales, M.; Mora Rodríguez, JDJ. (2018). Validation of a Computational Fluid Dynamics Model for a Novel Residence Time Distribution Analysis in Mixing at Cross-Junctions. Water. 10(6):1-18. https://doi.org/10.3390/w10060733S118106Mercier Shanks, C., Sérodes, J.-B., & Rodriguez, M. J. (2013). Spatio-temporal variability of non-regulated disinfection by-products within a drinking water distribution network. Water Research, 47(9), 3231-3243. doi:10.1016/j.watres.2013.03.033Vasconcelos, J. J., Rossman, L. A., Grayman, W. M., Boulos, P. F., & Clark, R. M. (1997). Kinetics of chlorine decay. Journal - American Water Works Association, 89(7), 54-65. doi:10.1002/j.1551-8833.1997.tb08259.xOzdemir, O. N., & Ucak, A. (2002). Simulation of Chlorine Decay in Drinking-Water Distribution Systems. Journal of Environmental Engineering, 128(1), 31-39. doi:10.1061/(asce)0733-9372(2002)128:1(31)Knobelsdorf Miranda, J., & Mujeriego Sahuquillo, R. (1997). Crecimiento bacteriano en las redes de distribución de agua potable: una revisión bibliográfica. Ingeniería del agua, 4(2). doi:10.4995/ia.1997.2719Wang, W., Ye, B., Yang, L., Li, Y., & Wang, Y. (2007). Risk assessment on disinfection by-products of drinking water of different water sources and disinfection processes. Environment International, 33(2), 219-225. doi:10.1016/j.envint.2006.09.009Parks, S. L. I., & VanBriesen, J. M. (2009). Booster Disinfection for Response to Contamination in a Drinking Water Distribution System. Journal of Water Resources Planning and Management, 135(6), 502-511. doi:10.1061/(asce)0733-9496(2009)135:6(502)Hernández Cervantes, D., Mora Rodríguez, J., Delgado Galván, X., Ortiz Medel, J., & Jiménez Magaña, M. R. (2015). Optimal use of chlorine in water distribution networks based on specific locations of booster chlorination: analyzing conditions in Mexico. Water Supply, 16(2), 493-505. doi:10.2166/ws.2015.161Weickgenannt, M., Kapelan, Z., Blokker, M., & Savic, D. A. (2010). Risk-Based Sensor Placement for Contaminant Detection in Water Distribution Systems. Journal of Water Resources Planning and Management, 136(6), 629-636. doi:10.1061/(asce)wr.1943-5452.0000073Rathi, S., & Gupta, R. (2013). Monitoring stations in water distribution systems to detect contamination events. ISH Journal of Hydraulic Engineering, 20(2), 142-150. doi:10.1080/09715010.2013.857470Seth, A., Klise, K. A., Siirola, J. D., Haxton, T., & Laird, C. D. (2016). Testing Contamination Source Identification Methods for Water Distribution Networks. Journal of Water Resources Planning and Management, 142(4), 04016001. doi:10.1061/(asce)wr.1943-5452.0000619Xuesong, Y., Jie, S., & Chengyu, H. (2017). Research on contaminant sources identification of uncertainty water demand using genetic algorithm. Cluster Computing, 20(2), 1007-1016. doi:10.1007/s10586-017-0787-6Rathi, S., & Gupta, R. (2015). Optimal sensor locations for contamination detection in pressure-deficient water distribution networks using genetic algorithm. Urban Water Journal, 14(2), 160-172. doi:10.1080/1573062x.2015.1080736Sandoval, M. A., Fuentes, R., Walsh, F. C., Nava, J. L., & de León, C. P. (2016). Computational fluid dynamics simulations of single-phase flow in a filter-press flow reactor having a stack of three cells. Electrochimica Acta, 216, 490-498. doi:10.1016/j.electacta.2016.09.045Castañeda, L. (2017). Computational Fluid Dynamic Simulations of Single-Phase Flow in a Spacer-Filled Channel of a Filter-Press Electrolyzer. International Journal of Electrochemical Science, 7351-7364. doi:10.20964/2017.08.09Song, I., Romero-Gomez, P., & Choi, C. Y. (2009). Experimental Verification of Incomplete Solute Mixing in a Pressurized Pipe Network with Multiple Cross Junctions. Journal of Hydraulic Engineering, 135(11), 1005-1011. doi:10.1061/(asce)hy.1943-7900.0000095Romero-Gomez, P., Lansey, K. E., & Choi, C. Y. (2010). Impact of an incomplete solute mixing model on sensor network design. Journal of Hydroinformatics, 13(4), 642-651. doi:10.2166/hydro.2010.123Yu, T. C., Shao, Y., & Shen, C. (2014). Mixing at Cross Joints with Different Pipe Sizes in Water Distribution Systems. Journal of Water Resources Planning and Management, 140(5), 658-665. doi:10.1061/(asce)wr.1943-5452.0000372Shao, Y., Jeffrey Yang, Y., Jiang, L., Yu, T., & Shen, C. (2014). Experimental testing and modeling analysis of solute mixing at water distribution pipe junctions. Water Research, 56, 133-147. doi:10.1016/j.watres.2014.02.053Mompremier, R., Pelletier, G., Fuentes Mariles, Ó. A., & Ghebremichael, K. (2015). Impact of incomplete mixing in the prediction of chlorine residuals in municipal water distribution systems. Journal of Water Supply: Research and Technology - Aqua, 64(8), 904-914. doi:10.2166/aqua.2015.148McKenna, S. A., O’Hern, T., & Hartenberger, J. (2009). Detailed Investigation of Solute Mixing in Pipe Joints through High Speed Photography. Water Distribution Systems Analysis 2008. doi:10.1061/41024(340)88Ho, C. K., & O’Rear, L. (2009). Evaluation of solute mixing in water distribution pipe junctions. Journal - American Water Works Association, 101(9), 116-127. doi:10.1002/j.1551-8833.2009.tb09964.xChoi, C. Y., Shen, J. Y., & Austin, R. G. (2009). Development of a Comprehensive Solute Mixing Model (AZRED) for Double-Tee, Cross, and Wye Junctions. Water Distribution Systems Analysis 2008. doi:10.1061/41024(340)89Rosales, M., Pérez, T., & Nava, J. L. (2016). Computational fluid dynamic simulations of turbulent flow in a rotating cylinder electrode reactor in continuous mode of operation. Electrochimica Acta, 194, 338-345. doi:10.1016/j.electacta.2016.02.076Moncho-Esteve, I. J., Palau-Salvador, G., Brevis, W., Vaas, M. O., & López-Jiménez, P. A. (2015). Numerical simulation of the hydrodynamics and turbulent mixing process in a drinking water storage tank. Journal of Hydraulic Research, 53(2), 207-217. doi:10.1080/00221686.2014.98945

Ileal apparent and standardized amino acid digestibility of soybean and colza meal in diets for finishing pigs

Agri-food chains generate by-products such as soybean and colza meal for animal feed. Their nutritional value is variable and should be analysed for better quality control before their inclusion in balanced diets. The objective was to determine the content and ileal apparent and standardized digestibility of protein and amino acids (AA) of soybean (PS) and colza meal (PC) as a source of protein in diets for finishing pigs. The experimental units were arranged in a 3×3 Latin square design repeated. The treatments (T) were T1: PS+corn starch, T2: PC+corn starch, and T3: corn starch (Control), which were randomly assigned to six pigs cannulated in distal ileum (PV 75±1.2 kg). The variables were contents and apparent ileal and standardized ileal digestibility of amino acids in soybean and colza meal. To determine digestibility, chromic oxide was added to the diets. The protein and fat contents were higher in the soybean meal. Ash, crude fibre, neutral detergent fibre, acid detergent fibre, phosphorus and calcium contents were higher in the colza meal. Essential amino acid content was higher in soybean meal, but methionine was higher in colza meal. Apparent ileal digestibility (DIA) of total amino acids was similar (p > 0.05) among protein ingredients; but for lysine and threonine it was higher (p ≤ 0.05) in soybean meal, except methionine. Methionine DIA was 89.78 %, 3.88 % higher (p ≤ 0.05) in colza meal. Standardized ileal digestibility (DIE) of total amino acids was similar (p > 0.05) among ingredients, but lysine and threonine were higher (p ≤ 0.05) in soybean meal. DIE was different (p ≤ 0.05) among ingredients for all amino acids except methionine. Ileal and standardized digestibility of all amino acids were higher in soybean meal, except methionine, which was higher in colza meal. The DIA of total amino acids was similar in both protein ingredients, except lysine and threonine in soybean meal and methionine in colza meal

The Fourteenth Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the extended Baryon Oscillation Spectroscopic Survey and from the second phase of the Apache Point Observatory Galactic Evolution Experiment

The fourth generation of the Sloan Digital Sky Survey (SDSS-IV) has been in operation since July 2014. This paper describes the second data release from this phase, and the fourteenth from SDSS overall (making this, Data Release Fourteen or DR14). This release makes public data taken by SDSS-IV in its first two years of operation (July 2014-2016). Like all previous SDSS releases, DR14 is cumulative, including the most recent reductions and calibrations of all data taken by SDSS since the first phase began operations in 2000. New in DR14 is the first public release of data from the extended Baryon Oscillation Spectroscopic Survey (eBOSS); the first data from the second phase of the Apache Point Observatory (APO) Galactic Evolution Experiment (APOGEE-2), including stellar parameter estimates from an innovative data driven machine learning algorithm known as "The Cannon"; and almost twice as many data cubes from the Mapping Nearby Galaxies at APO (MaNGA) survey as were in the previous release (N = 2812 in total). This paper describes the location and format of the publicly available data from SDSS-IV surveys. We provide references to the important technical papers describing how these data have been taken (both targeting and observation details) and processed for scientific use. The SDSS website (www.sdss.org) has been updated for this release, and provides links to data downloads, as well as tutorials and examples of data use. SDSS-IV is planning to continue to collect astronomical data until 2020, and will be followed by SDSS-V.Comment: SDSS-IV collaboration alphabetical author data release paper. DR14 happened on 31st July 2017. 19 pages, 5 figures. Accepted by ApJS on 28th Nov 2017 (this is the "post-print" and "post-proofs" version; minor corrections only from v1, and most of errors found in proofs corrected

Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

Background: Despite remarkable achievements in antiretroviral therapy (ART), losses to follow-up (LTFU) might prevent the long-term success of HIV treatment and might delay the achievement of the 90-90-90 objectives. This scoping review is aimed at the description and analysis of the strategies used in high-income countries to reengage LTFU in HIV care, their implementation and impact. Methods: A scoping review was done following Arksey & O'Malley's methodological framework and recommendations from Joanna Briggs Institute. Peer reviewed articles were searched for in Pubmed, Scopus and Web of Science; and grey literature was searched for in Google and other sources of information. Documents were charted according to the information presented on LTFU, the reengagement procedures used in HIV units in high-income countries, published during the last 15 years. In addition, bibliographies of chosen articles were reviewed for additional articles. Results: Twenty-eight documents were finally included, over 80% of them published in the United States later than 2015. Database searches, phone calls and/or mail contacts were the most common strategies used to locate and track LTFU, while motivational interviews and strengths-based techniques were used most often during reengagement visits. Outcomes like tracing activities efficacy, rates of reengagement and viral load reduction were reported as outcome measures. Conclusions: This review shows a recent and growing trend in developing and implementing patient reengagement strategies in HIV care. However, most of these strategies have been implemented in the United States and little information is available for other high-income countries. The procedures used to trace and contact LTFU are similar across reviewed studies, but their impact and sustainability are widely different depending on the country studied

XXV Curso Monográfico de Psiquiatría Infantil y la Adolescencia: Tópicos de Psicofarmacología Infantil - 2023

El XXV Curso Monográfico de Psiquiatría Infantil y de la Adolescencia, titulado "Tópicos de Psicofarmacología Infantil," fue un evento destacado en el campo de la salud mental infantil y adolescente. Durante tres días en septiembre de 2023, expertos líderes en la materia se reunieron para explorar a fondo la psicofarmacología en este grupo de edad. El evento, dedicado a la memoria del Dr. Francisco Javier Valencia Granados, comenzó con una ceremonia de inauguración en la que participaron autoridades institucionales. Luego, se sucedieron conferencias magistrales que abordaron una amplia variedad de temas cruciales. Estos incluyeron aspectos fundamentales como la neurobioquímica farmacológica y una introducción a la psicofarmacología. El programa se adentró en cuestiones específicas, como el uso de antipsicóticos en paidopsiquiatría, el abordaje de trastornos del aprendizaje, el tratamiento del suicidio desde una perspectiva psicofarmacológica, y la gestión farmacológica del insomnio en niños. Se exploraron temas especializados, como el tratamiento de la esquizofrenia en pacientes infantiles. El segundo día se centró en trastornos emocionales en niños y adolescentes, destacando el tratamiento del trastorno depresivo, los trastornos ansiosos y el espectro autista. Se presentaron enfoques vanguardistas, como el uso de psicodélicos en adolescentes y las novedades en psicofarmacología, como el dextrometorfano y el bupropión. También se discutió el manejo de la epilepsia y la adicción a los videojuegos. El tercer día se enfocó en el tratamiento farmacológico de trastornos pediátricos específicos, como el trastorno bipolar, el déficit de atención e hiperactividad, la enuresis y encopresis, parasomnias, y el abordaje neuropsiquiátrico en pacientes pediátricos con VIH. Se exploraron también trastornos de la conducta alimentaria y la disforia de género. El evento culminó con una reflexión sobre la salud mental en niños y un emotivo tributo al Dr. Francisco Javier

The 16th Data Release of the Sloan Digital Sky Surveys : First Release from the APOGEE-2 Southern Survey and Full Release of eBOSS Spectra

This paper documents the 16th data release (DR16) from the Sloan Digital Sky Surveys (SDSS), the fourth and penultimate from the fourth phase (SDSS-IV). This is the first release of data from the Southern Hemisphere survey of the Apache Point Observatory Galactic Evolution Experiment 2 (APOGEE-2); new data from APOGEE-2 North are also included. DR16 is also notable as the final data release for the main cosmological program of the Extended Baryon Oscillation Spectroscopic Survey (eBOSS), and all raw and reduced spectra from that project are released here. DR16 also includes all the data from the Time Domain Spectroscopic Survey and new data from the SPectroscopic IDentification of ERosita Survey programs, both of which were co-observed on eBOSS plates. DR16 has no new data from the Mapping Nearby Galaxies at Apache Point Observatory (MaNGA) survey (or the MaNGA Stellar Library "MaStar"). We also preview future SDSS-V operations (due to start in 2020), and summarize plans for the final SDSS-IV data release (DR17).Peer reviewe

The Fifteenth Data Release of the Sloan Digital Sky Surveys: First Release of MaNGA-derived Quantities, Data Visualization Tools, and Stellar Library

Twenty years have passed since first light for the Sloan Digital Sky Survey (SDSS). Here, we release data taken by the fourth phase of SDSS (SDSS-IV) across its first three years of operation (2014 July–2017 July). This is the third data release for SDSS-IV, and the 15th from SDSS (Data Release Fifteen; DR15). New data come from MaNGA—we release 4824 data cubes, as well as the first stellar spectra in the MaNGA Stellar Library (MaStar), the first set of survey-supported analysis products (e.g., stellar and gas kinematics, emission-line and other maps) from the MaNGA Data Analysis Pipeline, and a new data visualization and access tool we call "Marvin." The next data release, DR16, will include new data from both APOGEE-2 and eBOSS; those surveys release no new data here, but we document updates and corrections to their data processing pipelines. The release is cumulative; it also includes the most recent reductions and calibrations of all data taken by SDSS since first light. In this paper, we describe the location and format of the data and tools and cite technical references describing how it was obtained and processed. The SDSS website (www.sdss.org) has also been updated, providing links to data downloads, tutorials, and examples of data use. Although SDSS-IV will continue to collect astronomical data until 2020, and will be followed by SDSS-V (2020–2025), we end this paper by describing plans to ensure the sustainability of the SDSS data archive for many years beyond the collection of data

The 16th Data Release of the Sloan Digital Sky Surveys: First Release from the APOGEE-2 Southern Survey and Full Release of eBOSS Spectra

This paper documents the 16th data release (DR16) from the Sloan Digital Sky Surveys (SDSS), the fourth and penultimate from the fourth phase (SDSS-IV). This is the first release of data from the Southern Hemisphere survey of the Apache Point Observatory Galactic Evolution Experiment 2 (APOGEE-2); new data from APOGEE-2 North are also included. DR16 is also notable as the final data release for the main cosmological program of the Extended Baryon Oscillation Spectroscopic Survey (eBOSS), and all raw and reduced spectra from that project are released here. DR16 also includes all the data from the Time Domain Spectroscopic Survey and new data from the SPectroscopic IDentification of ERosita Survey programs, both of which were co-observed on eBOSS plates. DR16 has no new data from the Mapping Nearby Galaxies at Apache Point Observatory (MaNGA) survey (or the MaNGA Stellar Library "MaStar"). We also preview future SDSS-V operations (due to start in 2020), and summarize plans for the final SDSS-IV data release (DR17)

The 16th Data Release of the Sloan Digital Sky Surveys: First Release from the APOGEE-2 Southern Survey and Full Release of eBOSS Spectra

This paper documents the 16th data release (DR16) from the Sloan Digital Sky Surveys (SDSS), the fourth and penultimate from the fourth phase (SDSS-IV). This is the first release of data from the Southern Hemisphere survey of the Apache Point Observatory Galactic Evolution Experiment 2 (APOGEE-2); new data from APOGEE-2 North are also included. DR16 is also notable as the final data release for the main cosmological program of the Extended Baryon Oscillation Spectroscopic Survey (eBOSS), and all raw and reduced spectra from that project are released here. DR16 also includes all the data from the Time Domain Spectroscopic Survey and new data from the SPectroscopic IDentification of ERosita Survey programs, both of which were co-observed on eBOSS plates. DR16 has no new data from the Mapping Nearby Galaxies at Apache Point Observatory (MaNGA) survey (or the MaNGA Stellar Library "MaStar"). We also preview future SDSS-V operations (due to start in 2020), and summarize plans for the final SDSS-IV data release (DR17)

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline